It is an optimized Toll-like receptor 3 (TLR3) agonist and endogenous interferon (IFN) inducer in late-stage clinical development, with the ability to augment both innate and acquired immunity including cellular responses, like T cell response, in humans with immunodeficiency (HIV disease) [30]. This evidence concerns the gene TLR3 and Immunodeficiency.